Flow Cytometry Assay Validation as a Biomarker Versus in a Drug Development Setting

Home > Science Hub > Flow Cytometry Assay Validation as a Biomarker Versus in a Drug Development Setting
Back to the list

June 9, 2018

Audrey Gagnon, Dominic Gagnon, Jean-Francois Poulin, Bader Yassine-Diab, Martin Lelaidier, Virginia Litwin

Flow Cytometry Assay Validation as a Biomarker Versus in a Drug Development Setting, ICCS Annual Meeting / Annual Clinical Cytometry Meeting 2018

Flow-Cytometry-Assay-Validation-as-a-Biomarker-Versus-in-a-Drug-Development-Setting

Download poster

You might also be interested by

Brochures

Cell Therapy

December 15, 2023

Histopathology

More info

Infographics

Next-Generation Flow Cytometry Analysis with CellEngine™

January 31, 2023

Immune Monitoring

More info

CellTalk Blog

Discover Metadata-Driven Cytometry Analysis With CellEngine™

January 31, 2023

Immune Monitoring

More info

CellTalk Blog

Easy, Customized Autogating With CellEngine™

December 14, 2022

Immune Monitoring

More info